Therapeutic Drug Monitoring of Cariprazine – Updated Values for a
                    Dose-Related Reference Range

Fabian Sattaf; Maike Scherf-Clavel; Stefan Unterecker; Andreas Eckert; Andreas Reif; Martina Hahn

doi:10.1055/a-2511-3744

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2025; 58(03): 127-131
DOI: 10.1055/a-2511-3744

Original Paper

Therapeutic Drug Monitoring of Cariprazine – Updated Values for a Dose-Related Reference Range

Authors

Fabian Sattaf

¹Department of Psychiatry, Psychosomatics and Psychotherapy University Hospital Frankfurt, Germany
Maike Scherf-Clavel

²Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
Stefan Unterecker

²Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
Andreas Eckert

¹Department of Psychiatry, Psychosomatics and Psychotherapy University Hospital Frankfurt, Germany
Andreas Reif

¹Department of Psychiatry, Psychosomatics and Psychotherapy University Hospital Frankfurt, Germany
Martina Hahn

¹Department of Psychiatry, Psychosomatics and Psychotherapy University Hospital Frankfurt, Germany

³Department of Mental Health, Varisano Hospital Frankfurt Hoechst, Frankfurt, Germany

Abstract

Background

Dose-related reference ranges can be used in therapeutic drug monitoring to monitor pharmacotherapy. The deviation of a measured serum concentration from the expected serum concentration at the corresponding dose can thus be identified early and responded to appropriately. The serum concentrations of patients treated with cariprazine regularly deviated from this dose-related reference range. As this is a relatively new drug with only one recommendation on values for a dose-related reference range, the values were tested for validity using real-world data.

Methods

Serum concentrations of 24 patients receiving cariprazine once daily were analyzed retrospectively. Only patients without pharmacokinetic abnormalities were included. The measured serum concentrations were compared with the values of the dose-related reference range in the guidelines of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie consensus guidelines of 2017 and checked whether a sufficient number of serum concentrations were within the dose-related reference range.

Results

Only 45.8% of the measured serum concentrations were within the dose-related reference range. The C/D ratio was 1.58±0.73. Accordingly, a lower value of 0.85 and an upper value of 2.31 were calculated for the updated dose-related reference range, which is below the currently recommended values.

Conclusion

The results suggest that the current values for the dose-related reference range are too high and require adjustment. The updated dose-related reference range lies between 0.85 and 2.31, with a mean of 1.58±0.73.

Keywords

cariprazine - dose-related reference range - therapeutic drug monitoring - AGNP consensus guidelines

Full Text

References

References
1 Cooper H, Mishriky R, Reyad AA. Efficacy and safety of cariprazine in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials. Psychiatr Danub 2020; 32: 36-45
2 Calabrese JR, Keck PE, Starace A. et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: A double-blind, placebo-controlled study. J Clin Psychiatry 2015; 76: 284-292
3 Durgam S, Earley W, Guo H. et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry 2016; 77: 371-378
4 Durgam S, Greenberg WM, Li D. et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: Results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl) 2017; 234: 199-209
5 Kane JM, Zukin S, Wang Y. et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results from an international, phase III clinical trial. J Clin Psychopharmacol 2015; 35: 367-373
6 Ketter TA, Sachs GS, Durgam S. et al. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. J Affect Disord 2018; 225: 350-356
7 Vieta E, Earley WR, Burgess MV. et al. Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder. Int Clin Psychopharmacol 2019; 34: 76-83
8 Haen E, Greiner C, Bader W. et al. Wirkstoffkonzentrationsbestimmungen zur therapieleitung. Ergänzung therapeutischer Referenzbereiche durch dosisbezogene Referenzbereiche. Nervenarzt 2008; 79: 558-566
9 Hiemke C, Bergemann N, Clement HW. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: e1-e62
10 Hiemke C. Concentration-effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges. Ther Drug Monit 2019; 41: 174-179
11 Haen E. Dose-related reference range as a tool in therapeutic drug monitoring. Ther Drug Monit 2022; 44: 475-493
12 Ritscher S, Hoyer M, Wunder C. et al. Evaluation of the dose-related concentration approach in therapeutic drug monitoring of diuretics and β-blockers – drug classes with low adherence in antihypertensive therapy. Sci rep 2019; 9: 15652
13 Rancic N, Dragojevic-Simic V, Vavic N. et al. Tacrolimus concentration/dose ratio as a therapeutic drug monitoring strategy: The influence of gender and comedication. Vojnosanit Pregl 2015; 72: 813-822
14 van Gelder T, Meziyerh S, Swen JJ. et al. The clinical impact of the C0/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients. Front Pharmacol 2020; 11: 1142
15 Nakamura T, Kubota T, Iwakaji A. et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther 2016; 10: 327-338
16 Hiemke C, Baumann P, Bergemann N. et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry 2011; 44: 195-235
17 Hefner G, Hahn M, Buenger M. et al. Comparison of dose-related-reference ranges with individual psychotropic drug serum concentrations in clinical practice – AGNP consensus guidelines 2011 and 2017. J Pharmacol Pharm Res 2017; 1: 001
18 Periclou A, Phillips L, Ghahramani P. et al. Population pharmacokinetics of cariprazine and its major metabolites. Eur J Drug Metab Pharmacokinet 2021; 46: 53-69
19 Schoretsanitis G, Kane JM, Correll CU. et al. Blood levels to optimize antipsychotic treatment in clinical practice: A joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry 2020; 81: 81
20 Sattaf F, Scherf-Clavel M, Unterecker S. et al. Recommendation for a therapeutic reference range of cariprazine-a short communication. Ther drug monit 2024; 46: 270-273
21 Kiss B, Némethy Z, Fazekas K. et al. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine. Drug Des Devel Ther 2019; 13: 3229-3248
22 Fekete S, Hiemke C, Gerlach M. Dose-related concentrations of neuroactive/psychoactive drugs expected in blood of children and adolescents. Ther Drug Monit 2020; 42: 315-324
23 Hart XM, Gründer G, Ansermot N. et al. Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics. World J Biol Psychiatry 2024; 25: 451-536
24 Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 1999; 24: 339-346
25 Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med 2009; 24: 1-10
26 Haen E. Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety. Pharmacopsychiatry 2011; 44: 254-258